Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Fulvestrant 8olaparib 4Capecitabine 4pyrotinib 3Docetaxel 3toripalimab 2Vinorelbine 2Trastuzumab 2Letrozole 2Injections 2Goserelin 2Alpelisib 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1sacituzumab govitecan 1pembrolizumab 1neratinib 1liposomal doxorubicin 1exemestane 1eribulin 1dalpiciclib 1ceralasertib 1cediranib 1capivasertib 1abemaciclib 1Tablets 1Paclitaxel 1Moxifloxacin 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Cancer × talazoparib × Clear all
NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Seoul National University Hospital

Phase 2 Recruiting
70 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡